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Interleuk¡n-4 (IL-4) Inhibits Secretion of IL-1/9, Tumor Necrosis Factor a,
and IL-6 by Human Monocytes
By Anje A. te Velde, Richard J.F. Huijbens, Kees Heije, Jan E. de Vries, and Carl G. Fjgdor
Monocytes activated by lipopolysaccharide (LPS) and inter­
feron y  (IFN7 ) rapidly secrete a number of monokines with  
different functional properties. Interleukin-4 (IL-4), a T-cell 
derived cytokine, has been shown to reduce the production 
of monokines with cytostatic activity for tumor cells, 
chemotactic activity for monocytes, and factors that stimu­
late thymocyte proliferation. This latter activity is medi­
ated by a number of monokines like IL-1 , tumor necrosis 
factor a {TNFa), and IL-6. To elucidate which cytokines 
produced by monocytes are controlled by IL-4, we tested 
the effect of IL-4 on the secretion of IL-1 a , IL-1 ß, TNFa, and 
IL-6 induced by LPS or IFN7 . IL-4 was found to inhibit the 
secretion of IL-1/? and TNFa by activated monocytes
HUMAN RECOMBINANT interleukin-4 (IL-4) has pleiotropic effects.1 IL-4 has been shown to act as a 
growth factor for activated T cells, thymocytes, natural killer 
cells, and B cells.2,3 IL-4 can enhance specific cytotoxic T 
lymphocyte (CTL) activity4 but suppresses IL-2-induced 
lymphokine activated killer (LAK) cell activity.4,5 IL-4 
induces the expression of class II major histocompatibility 
complex (MHC) antigens on normal and malignant B cells6 
as well as on peripheral blood monocytes.7
Recently we demonstrated that monocytes cultured with 
IL-4 show a reduced production of factors with cytostatic 
activity against melanoma cells and with chemotactic activ­
ity for monocytes.7 Initial experiments showed that IL-4 
inhibited the production of IL-1-like activity as judged by 
the reduced ability of culture supernatants of these cells to 
costimulate (with Con A) the proliferation of murine 
thymocytes.7 However, this thymocyte assay does not specif­
ically detect monocyte products like IL-18 because tumor 
necrosis factor a (TNFa)9'11 and IL-612,13 can also stimulate 
thymocyte proliferation.
This prompted us to study whether IL-4 reduces the 
production of one or more of these monokines. We used 
IL-1 a, IL-lß, TNFa, and IL-6 immunoassays to directly 
study the effect of IL-4 on synthesis of these monokines by 
monocytes. Because monocytes generally need to be stimu­
lated to produce significant levels of monokines in in vitro 
culture,14'19 we studied monokine secretion after activation 
with lipopolysaccharide (LPS) or interferon 7  (IFN7 ). The
From the Division of Immunology, The Netherlands Cancer 
Institute, Amsterdam, and DNAX Research Institute of Molecular 
and Cellular Biology, Inc, Palo Alto, CA.
Submitted April 27, 1989; accepted June 6,1990.
Supported by Grant NKI 86-1 from the Koningin Wil hel mina 
Fonds (The Netherlands Cancer Foundation).
Address reprint requests to A.A. te Velde, Division of Immunol­
ogy, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX 
Amsterdam, The Netherlands.
The publication costs of this article were defrayed in part by page 
charge payment. This article must therefore be hereby marked 
“advertisement” in accordance with 18 U.S.C. section 1734 solely to 
indicate this fact.
© 1990 by The American Society of Hematology.
0006-4971/90/7607-0025$3.00/0
almost 100%. The secretion of IL-6  was found to be 
reduced 70% to 85% in the presence of IL-4, whereas there 
was no effect on the secretion of IL-1 a  {IL-1 a  is mainly 
cell-associated). Time-course experiments demonstrate 
that IL-4 reduces the secretion of monokines for a pro­
longed period of time (>40 hours). The reduced secretion 
of IL-1 ß and TNFa was specifically induced by IL-4 because 
anti-IL-4 antiserum completely restored normal monokine 
production. These data suggest that IL-4 plays a role in the 
regulation of immune responses by reducing the produc­
tion of functionally important monokines.
© 1990 by The American Society of Hematology.
data described here show that IL-4 inhibits the secretion of 
IL-1/3, TNFa, and IL-6 by monocytes on activation, suggest­
ing that IL-4 is involved in the regulation of the production of 
monokines by human monocytes,
MATERIALS AND METHODS
Isolation and culture of human monocytes. Human peripheral 
blood monocytes were isolated from 500 mL blood of normal human 
donors, as described previously.20,21 Mononuclear cells were isolated 
by density centrifugation in a blood component separator, followed 
by fractionation into lymphocytes and monocytes by centrifugal 
élutriation. The monocyte preparation was over 95% pure, as judged 
by nonspecific esterase staining and contained more than 98% viable 
cells. Monocytes were cultured in Yssel’s medium22 containing 
human serum albumin (HSÀ) and supplemented with 1% autolo­
gous or pooled heat-inactivated human serum. This culture medium 
was endotoxin free as determined by the Limulus amebocyte lysate 
assay (<0.2 ng/mL of endotoxin). The monocytes were incubated at 
a concentration of 4 x 106 cells/mL in Teflon bags (Jansen MNL, St 
Niklaas, Belgium).
After culture for 2 to 40 hours, monocyte culture supernatants 
were collected for determination of IL-1 a, IL-10, TNFa, and IL-6 . 
The viability of the cells determined by trypan blue exclusion always 
exceeded 90%.
Recombinant IL-4, LPS, IFNy, and anti-IL-4 serum. 
Recombinant human IL-4 was obtained as a purified protein from 
supernatants of L cells transfected with the cDNA clone encoding 
IL-4 (specific activity 107 U/mL), kindly provided by Dr S. 
Nagabhushan (Schering-Plough Corp, Bloomfield, NY). One unit of 
IL-4 was defined as the concentration of IL-4 resulting in half- 
maximal proliferation of phytohemagglutinin-activated T 
lymphoblasts.23 LPS (Escherichia coli 0127:B8) was obtained from 
Difco Laboratories (Detroit, MI). Human recombinant IFN7  (sPe" 
cific activity 107 U/mg was kindly provided by Drs P. Trotta and S. 
Naghabhushan (Schering-Plough Corp). The polyclonal rabbit 
anti-IL-4 antiserum that blocks the biologic activity of IL-4 has 
been described previously.24 This antibody is specific for IL-4 and 
blocks IL-4—induced proliferation of T cells,2 B cells,24 and IL-4- 
induced immunoglobulin E synthesis.25,26
Detection of IL-1 a, IL-lß, TNFa, and IL-6 in monocyte culture 
supernatant. IL-1 a in the culture supernatant of human mono­
cytes was tested using the Endogen IL- la enzyme-linked immunosor­
bent assay (ELISA) (Endogen Inc, Boston, MA). The sensitivity of 
this assay is 50 pg/mL of IL-la and there is no cross-reactivity with 
IL-1/3, IL-2, IFNs, IL-6 , TNFa, lymphotoxin, or other cytokines.
IL-lß in the culture supernatant of human monocytes was tested 
using the Cistron IL-1/3 ELISA (Cistron Biotechnology, Pine Brook,
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NJ). The sensitivity of this assay is 20 pg of IL-1/3 and there is no 
cross-reactivity with IL-1 a, IL-2, IFN7 , or TNFa.
TNFa in the culture supernatant of human monocytes was tested 
using the Biokine TNF Test Kit (T-Cell Sciences, Cambridge, MA). 
The sensitivity of this assay is 1 0  pg TNFa/mL and it shows no 
detectable cross-reactivity with any other cytokine.
IL - 6  in the culture supernatant of human monocytes was tested 
using the Research & Diagnostics Systems Quantikine human IL -6  
immunoassay (Minneapolis, MN)> The sensitivity of this assay is 3 .5  
pg/mL and it shows no detectable cross-reactivity with other 
cytokines,
RESULTS
IL-4 inhibits production of IL-lß, TNFa, and IL-6 by 
human monocytes. IL-1 a, IL-lß, TNFa, and IL-6 activity 
in the supernatant of IL-4-treated monocytes was tested 
using specific assays. Monocytes cultured for 4 hours in LPS 
secrete significant levels of IL-1/3, TNFa, and IL-6 (Fig 1)* 
IL-1 a is not secreted but this correlates with the observation 
that IL-1 a is predominantly membrane-associated, whereas 
IL-1/3 is mainly detected in the culture supernatant after cell 
activation.27 IL-4 downregulates the secretion of IL-lß, 
TNFa, and IL-6 by monocytes activated with LPS in a 
dose-dependent fashion (Fig 1). Addition of 10 U/mL of 
IL-4 already causes a 90% to 100% reduction of IL-1/3 and 
TNFa production by LPS-activated monocytes cultured for 
4 hours (Fig 1 ). IL-4 also reduces the secretion of IL-6, but in 
contrast to blocking of the IL-1/3 and TNFa production no 
complete inhibition is found (70% to 85%). These data 
demonstrate that IL-4 reduces the secretion of IL-lß, TNFa, 
and IL-6 by LPS-activated monocytes in a dose-dependent 
manner.
Although the monocyte preparations we used in this study 
were over 95% pure we cannot exclude that IL-4 exerts its 
effect indirectly by acting through contaminating cells. 
Moreover, it has been described that IL-4 has lymphocyte- 
activating activity.2 Therefore, we mixed pure monocytes 
with increasing concentrations of fractionated lymphocytes 
and studied the effect of IL-4 on the production of TNFa. 
The effect of IL-4 on the TNFa production is most promi­
nent if no lymphocytes are present (Fig 2) and the effect is 
measurable up to 50% contaminating lymphocytes. We have 
to take into account that in the presence of 50% lymphocytes 
the normal TNFa production of the monocytes is reduced 
with a factor 2 compared with 100% monocytes. Taken 
together these data demonstrate that IL-4 directly regulates 
this monocyte response and that lymphocytes have no effect.
The profound inhibition of IL-lß and TNFa production is 
specific for IL-4 because anti-IL-4 antiserum blocks the 
IL-4 effect. The inhibition of IL-lß and TNFa production by 
IL-4 is completely abrogated in the presence of an anti-IL-4 
antiserum at dilutions of 1:500 and 1:5,000. Blocking of 20% 
to 30% was achieved at a 1:50,000 dilution (Fig 3A), whereas 
normal control rabbit antiserum was ineffective (Fig 3B). 
The anti-IL-4 antiserum used in this study also blocked 
IL-4-induced upregulation of MHC class II antigen expres­
sion and induction of CD23 expression on human monocytes.28
Next we performed time-course experiments to character­
ize the kinetics of the effect of IL-4 on monokine secretion. 
The results in Fig 4 show that at all time points tested the
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Fig 1. Detection of 1L-1« (A), 1L-10 |B), TNFa (C), and IL-6 (D) 
in the culture supernatant of monocytes cultured for 4 hours with  
1 jxg/mL of LPS and increasing concentrations of IL-4. IL-1 a, IL-1/?, 
TNFa, and IL-6 were detected using specific non-cross-reactive 
ELIS As. Data of one representative experiment are shown.
secretion of IL-lß, TNFa, and IL -6 is reduced in the 
presence of IL-4. Up to 40 hours of culture reduced levels of 
IL-lß, TNFa, and IL-6 arc found in the presence of IL-4 
compared with-control cultures in LPS only. From these data 
we can conclude that IL-4 inhibits the secretion of monokines 
for a prolonged period of time (up to 40 hours) and that the 
effect cannot be ascribed to a delayed secretion of monokines 
by IL-4.
In addition, we tested the effect of IL-4 on the secretion of
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Fig 2. Effect of IL-4 on TNFa secretion by LPS (1 jug/mL) 
stimulated human monocytes in the presence of increasing concen­
trations of contaminating lymphocytes. TNFa was detected after 4  
hours of cocultivation using a specific non-cross-reactive ELISA. 
Data of one representative experiment are shown.
monokines induced by stimuli other than LPS, because it is 
described that not only LPS but also IFN7 can activate 
monocytes to produce monokines. Production of enhanced 
levels of IL-1/3 and TNFa by monocytes was found in the 
presence of IFNy ,17'19 while IFN7  has no effect on the 
production of IL-6.29 We detected secretion of IL-1/3 and of 
TNFct induced by IFNy (100 U/mL) in monocytes of three 
of six donors cultured for 20 hours. In all cases this secretion 
was reduced in the presence of IL-4 in a dose-dependent 
fashion (Fig 5), This result shows that IL-4 causes reduced 
IL-1/3 and TNFa secretion in monocytes irrespective of 
whether the cells were activated with LPS or IFN7 .
DISCUSSION
We previously demonstrated that monocytes cultured in 
the presence of IL-4 show a reduced secretion of factors with 
chemotactic activity, cytostatic activity, and factors that 
stimulate thymocyte proliferation.7 In this study we show 
that IL-4 reduces the secretion of IL-1/3 and TNFa by 
monocytes for almost 100%, whereas the secretion of IL-6 
was reduced for 70% to 85% in the presence of comparable 
levels of IL-4 (Fig 1). These results are in accordance with 
data of Essner et al29 who demonstrate similar effects of IL-4 
on the production of IL-1 and TNFa using bioassays to 
detect IL-1 (thymocyte assay) and TNFa (L929 cytotoxic 
assay). Because these assays possibly detect different factors, 
as already demonstrated for the thymocyte assay,8’13 we used 
non-cross-reactive specific ELIS As, which confirm and ex­
tend their data. Although we did not find any effect on the 
secretion of IL-1 a, Weiss et al30 demonstrated that monocyte 
cell-associated IL-la and IL-1/3 are reduced in monocytes 
cultured in the presence of IL-4. Yet their monocyte prepara­
tion was not pure and the cells were activated due to the 
isolation procedure.31 In this study we show that a contamina­
tion of up to 50% lymphocytes does not influence the effect of 
IL-4 on monokine production.
Is the reduced secretion of IL-lß, TNFa, and of IL-6 
responsible for the observed reduction in cytostatic and 
chemotactic activity? The experiments performed in this 
study demonstrate that IL-1/3 and TNFa secretion can be 
blocked for nearly 100% in the presence of IL-4. However, 
IL-4 does not completely block the production of cytostatic 
factors by monocytes as described previously.7 These experi­
ments showed that addition of 25% monocyte supernatant 
completely blocked the growth of A375 melanoma cells, and 
IL-4 displayed only a modest reducing effect on the produc-
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Fig 3. (A) Addition of increasing concentrations of anti-IL-4 
antiserum to human monocytes cultured in the presence of 100 
U/mL of IL-4 completely restores IL-1j3 and TNFa levels secreted 
in the culture medium after 4 hours of culture with 1 ¿ig/mL of 
LPS. (B) Normal rabbit control serum was ineffective. Monokine 
levels were determined using specific non-cross-reactive ELlSAs. 
Data of one representative experiment are shown.
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Fig 4. Time course of the production of IL-1/3 (A), TNFa (B), 
and IL-6 (C) by LPS (1 jitg/mL) stimulated monocytes with or 
without 100 U/mL of IL-4. Monokine levels were determined using 
specific non-cross-reactive ELISAs. Data of one representative 
experiment are shown.
tion of cytostatic compounds in the culture supernatant of 
monocytes (from 100% to 75% growth inhibition),7 This 
indicates that the cytostatic activity of monocyte supernatant 
cannot be explained by the presence of IL-1/3 and TNFa:, 
although these factors were repeatedly described to possess 
cytostatic activity.32'33 Evidence that this is the case comes 
from preliminary experiments with neutralizing antibodies 
directed against IL-1/3, TNFct, and IL-6. From these experi­
ments we can conclude that IL-6, not IL-1/3 and TNFa, was 
the major factor responsible for mediating cytostatic activity 
against A375 melanoma cells present in the monocyte 
supernatant (Te Velde AA, vd Wiel-v. Kemenade E, Figdor 
CG: submitted for publication). The observation that IL-4 
does not completely block the production of cytostatic factors 
by monocytes is in agreement with our findings that although 
the production of IL-1/3 and TNFa is almost completely 
blocked by IL-4, there is still some IL-6 activity left after 
IL-4 incubation. Further investigation is required to demon­
strate if the remaining cytostatic activity secreted by IL-4-
treated monocytes is mediated by IL-6 or can be ascribed to 
other yet unknown monocyte factors with cytostatic activity 
against melanoma cells.
When we used neutralizing antibodies against IL-1/3, 
TNFa, and IL-6 to neutralize chemotactic activity of the 
monocyte culture supernatants, we did not observe any 
significant neutralizing activity (not shown). From this 
experiment we can conclude that although IL-1 and TNFa 
have chemotactic activity for monocytes,34,35 the chemotactic 
factor(s) secreted in reduced amounts probably are not 
IL-1/3, TNFa, or IL-6 . A more likely candidate for this 
activity is the recently cloned monocyte chemotactic and 
activating factor (MCAF), secreted by monocytes.3*’37
How IL-4 influences the production of IL-1/3, TNFa, and 
IL-6 is not yet clear. Does IL-4 act directly on the production 
of these monokines or through intermediate factors? Because 
IL-1 can induce the production of IL-6 in fibroblasts and 
thymocytes,13,38 and monocytes,39 it is possible that the 
partially reduced IL-6 production is a consequence of re­
duced IL-1 production. In addition, IL-1 and TNF can 
induce each other’s release by monocytes.40,41 Although our 
experiments indicate that IL-1/3 and TNFa secretion are 
regulated similarly by IL-4, the regulation of TNF and IL-1 
production by monocytes is not identical and depends report­
edly on their differentiation state, exposure to lymphokines, 
microbial products, or other inflammatory inhibitors.42 Pre­
liminary studies indicate that IL-la, IL-1/3, TNFa, and IL-6 
steady-state messenger RNA (mRNA) levels are reduced in 
monocytes cultured in the presence of IL-4 (not shown), but 
more detailed studies are required to assess the relative 
contributions of changing rates of transcription and/or 
mRNA stability in determining the influence of IL-4 on 
monocyte steady-state mRNA levels.
IL-1 has been described as a costimulatory cytokine 
secreted by Ag presenting monocytes involved in T-lympho- 
cyte activation.43,44 Recently, TNFa and IL-6 were also
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Fig 5. IL-4 reduces IFNy  induced secretion of IL-1 and TNFa 
by human monocytes. Monocytes were cultured for 20 hours in 
100 U/mL of IFNy and increasing concentrations of IL-4. Monokine 
levels in the culture supernatant were determined using specific 
non-cross-reactive ELISAs. Data of one representative experi­
ment are shown.
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found to mediate enhancement of T-cell responses.45'47 In 
addition, the quantitative variation in expression of class II 
MHC Ag plays a major role in T-cell activation by Ag- 
presenting cells (APC).48 A number of studies (reviewed in 
reference 43) show that many of the modulators of IL-1 
production also affect the expression of MHC class II Ag in a 
coordinated fashion. This is of interest because we showed 
that IL-4 is able to upregulate the MHC class II Ag 
expression of human monocytes in a dose-dependent manner.7 
Thus, IL-4 downregulates IL-lß (and TNFa: and IL-6) 
production by human monocytes, but at the same time it 
enhances the expression of class II MHC antigens on these 
cells. Preliminary experiments investigating the APC func­
tion of human monocytes cultured in the presence of IL-4 
indicate that the APC function of human monocytes can be 
enhanced by IL-4 despite a reduced IL-1/3 secretion (Te 
Velde A A: manuscript in preparation). Similar results were 
reported by Zlotnik et al,49 who showed that IL-4 enhanced
the antigen-presenting capacity of murine bone marrow- 
derived macrophages.
A number of groups have initiated studies to investigate the 
possibility of combining IL-2 and IL-4 in immunotherapy.4,50 
Major drawbacks of high-dose IL-2 therapy are toxic side 
effects, which in part may be caused by the production of 
IL-1 and TNF.18,51 Preliminary in vitro data indicate that 
pre-exposure or simultaneous exposure to IL-4 reduces 
production of monokines by human monocytes activated by 
IL-2. Based on these in vitro results, it is tempting to 
speculate that IL-4 in combination with IL-2 may be used to 
generate cell populations from mononuclear cell suspensions 
with specific CTL activity5 and, potentially, with less toxic 
side effects.
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